Schwann Cells In Charcot Marie Tooth Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Schwann cells are the principal glial cells of the peripheral nervous system, providing myelination, trophic support, and metabolic maintenance for axons. Charcot-Marie-Tooth disease (CMT) represents the most common inherited peripheral neuropathy, with the majority of forms resulting from mutations affecting Schwann cell function. Understanding Schwann cell pathology in CMT provides critical insights into disease mechanisms and therapeutic strategies.
| Property | Value |
|----------|-------|
| Category | Glial Cells |
| Location | Peripheral Nervous System |
| Cell Type | Schwann cells (myelinating and non-myelinating) |
| Associated Disease | Charcot-Marie-Tooth Disease (CMT) |
| Inheritance | Autosomal dominant, recessive, X-linked |
- Myelinating Schwann cells (mSCs): Wrap large-diameter axons (>1μm)
- Remak Schwann cells (non-myelinating): Remak bundles of small axons
- Terminal Schwann cells: At neuromuscular junctions
- Satellite glial cells: Surround neuronal cell bodies in ganglia
- Internode: Compact myelin segments
- Node of Ranvier: Unmyelinated gaps between internodes
- ** Schmidt-Lanterman incisures**: Cytoplasmic channels
- Paranodal loops: Axoglial junctions
- Myelin proteins: PMP22, MPZ/P0, MBP, PLP
- Neuregulin-1: Axonal signal for myelination
- LGI1: Leukocyte-gene-like 1, synaptic maintenance
- Connexins: Gap junction proteins (Cx32, Cx29)
CMT encompasses a heterogeneous group of peripheral neuropathies:
CMT1 (Demyelinating)
- CMT1A: PMP22 duplication (most common)
- CMT1B: MPZ/P0 mutations
- CMT1X: GJB1 (Cx32) mutations
- CMT1F: NB1/NGF mutations
CMT2 (Axonal)
- CMT2A: MFN2 mutations
- CMT2B: RAB7 mutations
- CMT2K: GDAP1 mutations
CMT4 (Autosomal Recessive Demyelinating)
- CMT4A: GDAP1 mutations
- CMT4B1/B2: MTMR2, SBF2 mutations
- CMT4C: SH3TC2 mutations
CMT Intermediate
- DNM2 mutations
- YARS mutations
- PMP22 duplication: Overexpression causes myelin instability
- MPZ mutations: Abnormal myelin protein zero assembly
- GJB1 mutations: Gap junction dysfunction
- Abnormal compaction: Disrupted myelin structure
- Segmental demyelination: Focal myelin breakdown
- Onion bulb formation: Redundant Schwann cell processes
- Myelin thinning: Hypomyelination
- Demyelination-remyelination cycles: Repeated cycles lead to onion bulbs
- Secondary axonal loss: Results from demyelination
- Primary axonal involvement: In CMT2
- Wallerian degeneration: Distal axonal degeneration
- Slow progression: Gradual nerve fiber loss
- Autophagy defects: Accumulation of abnormal proteins
- Mitochondrial dysfunction: Energy impairment
- Endoplasmic reticulum stress: Unfolded protein response
- Impaired dedifferentiation: Failure to support regeneration
- Chronic demyelination: Leads to axonal degeneration
- Trophic factor deprivation: Impaired axonal support
- Calcium dysregulation: Excitotoxicity
- Oxidative stress: Free radical damage
- Length-dependent degeneration: "dying-back" neuropathy
- Distal-to-proximal progression: Early distal involvement
- Denervation: Muscle fiber loss
While CMT primarily affects peripheral nerves, recent studies suggest:
- Central nervous system involvement: Some CMT subtypes
- Cognitive function: Possible cognitive changes
- Neuroimaging findings: White matter changes
- PMP22 reduction: Antisense oligonucleotides
- Gene replacement: For recessive forms
- Gene editing: CRISPR-based approaches
- Viral vectors: AAV-mediated delivery
- Neurotrophic factors: BDNF, GDNF
- Antioxidants: Vitamin E, alpha-lipoic acid
- Anti-inflammatory: Curcumin
- Myelin stabilizers: Clemastine
- Schwann cell transplantation: Peripheral nerve repair
- iPSC-derived Schwann cells: Autologous transplantation
- Mesenchymal stem cells: Paracrine support
- Olfactory ensheathing cells: Nerve regeneration
- Physical therapy: Maintain muscle strength
- Occupational therapy: Adaptive strategies
- Orthopedic interventions: Prevent deformities
- Assistive devices: Mobility aids
- Trembler mouse: PMP22 point mutation
- Shambling mouse: Pmp22 deletion
- Cnp1 knockout: Myelin maintenance
- PMP22 transgenic: CMT1A model
- MPZ knockout: CMT1B model
- MFN2 mutants: CMT2A model
- Demyelination mechanisms: Pathway discoveries
- Therapeutic testing: Drug screening platforms
- Biomarkers: Disease progression markers
- Lupski & Reid, Charcot-Marie-Tooth disease (2010)
- Scherer & Wrabetz, Molecular mechanisms of CMT (2008)
- Pareyson et al., CMT1A pathogenesis (2009)
- Niemann et al., CMT4 subtypes (2006)
- Hattori & Yamamoto, Schwann cell therapy (2004)
- Kelley et al., CMT animal models (2014)
- Fledrich et al., Schwann cell pathology in CMT (2014)
- Sahenk & Reed, Gene therapy for CMT (2008)
The study of Schwann Cells In Charcot Marie Tooth Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.